Weight

The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence

The weight you lose and the nausea you experience from GLP-1 drugs may be linked to common gene variants, but they can’t fully explain why some people lose more weight than others

This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks

A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it

Obesity leaves a lasting imprint on fat and immune cells in ways that might make weight regain harder to avoid

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications

A new study suggests that people with obesity have higher rates of mortality and hospitalization from a variety of infections from viruses, fungi, parasites and bacteria

The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than current treatments. But experts wonder how much is too much

Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.

A new study finds that people who quit weight-loss medications, including GLP-1 drugs, regain weight four times faster than people who stop dieting or exercising

The first GLP-1 pills for weight loss are hitting U.S. pharmacies. But how will they be prescribed?

From immune cell therapies to measles outbreaks to federal attacks on public health, these are some of the health topics we’ll be watching next year